Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 3Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Myeloid 5Other hematologic neoplasm 2

Conditions

Thrombocythemia, Essential 3Polycythemia Vera 3Primary Myelofibrosis 2Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Extensive Stage Lung Small Cell Carcinoma 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
bomedemstat × Clear all
NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
20 enrolled 19 charts
Myeloid

Polycythemia Vera

NCT06351631 2026-04-02

MK-3543-017

Merck Sharp & Dohme LLC

Phase 3 Recruiting
400 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05597306 2026-01-08

VenBom

University of Miami

Phase 1 Recruiting
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04262141 2026-01-07

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

University of Miami

Phase 2 Active not recruiting
4 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT05223920 2025-09-22

MK-3543-005

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
81 enrolled 13 charts
Myeloid

Thrombocythemia, Essential, Primary Myelofibrosis

NCT05191797 2024-09-26

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

University of Washington

Phase 1/2 Terminated
3 enrolled 8 charts

Extensive Stage Lung Small Cell Carcinoma

NCT02842827 2023-07-11

IMG-7289-CTP-101

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 1/2 Completed
45 enrolled 41 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡